NCT05849675

Pitolisant Effects on Affect and Cognition Exploratory Study (PEACE Study)

An fMRI Investigation of the Effects of Selective Histamine-3 Receptor Antagonism on Cognitive and Emotional Processing in Healthy Individuals

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: University of Oxford · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to investigate the effects of selective histamine 3 antagonist pitolisant on brain function and cognition in healthy individuals. The main questions it aims to answer are: 1. Does pitolisant alter functional activity in brain regions linked to reward and cognitive processing during rest or cognitive task performance? 2. Does pitolisant alter cognitive ability across a range of psychological domains, including working memory, executive functioning and emotional processing? Participants will undertake fMRI scanning in addition to a battery of tasks designed to measure cognitive and emotional processing after taking a single dose of pitolisant or placebo. Researchers will compare differences in functional activity, cognition and emotional processing across the pitolisant and placebo groups.

Detailed description

Cognitive and affective processing are underpinned by monoaminergic neurotransmission and neurosteroid systems, yet there are many aspects of these systems that remain unknown in humans. In particular, monoaminergic histamine 3 (H3) receptors are abundant in CNS regions underpinning cognitive processing (prefrontal cortex, hippocampus, and striatum), yet the role of these receptors in humans remains unclear. Evidence from animal models suggests H3R antagonism improves cognitive functioning, however these specific effects are yet to be examined in humans. Similarly, the function of sigma-1 (σ-1) receptors in the brain is not well understood in humans despite strong evidence of pro-cognitive effects in animal models. The study will investigate the effect of pitolisant, a dual H3R antagonist and σ-1R agonist, on cognitive and affective processing, in addition to changes in functional connectivity. These effects will be measured with a battery of neuropsychological tasks (e.g., Affective Go/No-Go Task; Adaptive dual n-back task), self-rated measures of cognitive function (PDQ), and resting state fMRI and fMRI data acquisition during the verbal n-back and memory encoding tasks.

Conditions

• Anhedonia
• Cognitive Function

Interventions

Type	Name	Description
DRUG	Pitolisant 17.8 MG [Wakix]	Single dose pitoliosant (36mg)
DRUG	Placebo	Single dose placebo

Timeline

• Start date: 2023-04-01
• Primary completion: 2024-02-18
• Completion: 2024-05-08
• First posted: 2023-05-09
• Last updated: 2024-05-14

Locations

1 site across 1 country: United Kingdom